Ribon raises $65 million series B to target monoPARPs

A $65 million series B round will help Ribon Therapeutics Inc. (Lexington, Mass.) move its lead small molecule PARP-7 inhibitor into the clinic this year for squamous cell carcinoma of the lung. New investor Novartis Venture Fund led the round, which was announced Friday.

Novartis Venture's Anja Koenig told BioCentury the fund was attracted by a management team that has consistently hit milestones since Ribon’s $43 million series A round in 2015, and an IP portfolio that positions the company to "own a target class area" known as monoPARPs, which includes PARP-7...